A remarkable chemical compound born over a century ago in a lab, amphetamine’s potent but controversial journey from medicine to widespread abuse reveals a molecule of complex duality.
Key Takeaways
- Amphetamine was first synthesized in 1887 by Romanian chemist Lazăr Edeleanu.
- The chemical formula of amphetamine is C9H13N.
- Amphetamine has a molecular weight of 135.21 g/mol.
- Amphetamine is used to treat ADHD in children over 3 years old.
- Adderall (mixed amphetamine salts) is approved for narcolepsy.
- Dextroamphetamine (Dexedrine) treats ADHD at doses 5-40 mg/day.
- In 2021, 16 million US adults reported lifetime amphetamine misuse.
- Past-year amphetamine use disorder affected 1.3 million US people in 2021.
- Among US high school seniors, 3.9% used amphetamines nonmedically in 2022.
- Chronic high-dose amphetamine use causes dopamine transporter downregulation by 20-30%.
- Amphetamine overdose can cause hyperthermia up to 42°C.
- Cardiovascular risks include tachycardia; HR increases 20-50 bpm.
- Amphetamine is Schedule II under US Controlled Substances Act.
- Amphetamine possession illegal without prescription in most countries.
- DEA production quotas for amphetamine: 25,000 kg in 2023.
Amphetamines are prescribed for ADHD but also widely misused with significant risks.
Adverse Effects
1Chronic high-dose amphetamine use causes dopamine transporter downregulation by 20-30%.
Verified2Amphetamine overdose can cause hyperthermia up to 42°C.
Verified3Cardiovascular risks include tachycardia; HR increases 20-50 bpm.
Verified4Amphetamines associated with 2-4 fold increased stroke risk.
Directional5Psychosis incidence in chronic users: 20-40%.
Single source6Amphetamine withdrawal features depression in 60-80% of users.
Verified7Long-term use leads to dental decay ("meth mouth") in 30-50% of heavy users.
Verified8Amphetamines increase myocardial infarction risk by 3-fold acutely.
Verified9Neurotoxicity: amphetamine reduces striatal dopamine by 20-50% in primates.
Directional10Anxiety disorders in 25% of amphetamine-dependent individuals.
Single source11Skin picking and ulceration common; 40% of chronic users affected.
Verified12Amphetamine-induced cardiomyopathy in 10-15% of heavy users.
Verified13Cognitive deficits persist 1 year post-abstinence in 30% of users.
Verified14Hepatotoxicity risk elevated 2-fold with chronic use.
Directional15Amphetamines linked to rhabdomyolysis in overdose cases (5-10%).
Single source16Insomnia duration averages 3-5 days in binge use.
Verified17Amphetamines cause serotonin syndrome risk with SSRIs (rare, <1%).
Verified18Chronic use associated with Parkinson's-like symptoms in 10%.
Verified19Appetite suppression leads to 10-20% body weight loss in 6 months.
Directional20Psychotic symptoms resolve in 80% within 1 week abstinence.
Single source21Amphetamine elevates blood pressure by 10-20 mmHg systolic.
Verified22Seizure risk 2-5% in overdose.
Verified23Memory impairment: 15-25% deficit in chronic users.
Verified24Amphetamine vasoconstriction causes peripheral ischemia.
Directional25Renal failure in 5% of severe overdoses.
Single source26Aggression and violence 3-fold increased in users.
Verified27Amphetamine tolerance develops within weeks to dopamine effects.
Verified28Pulmonary hypertension risk with IV use (rare).
Verified29Sexual dysfunction: priapism in males (0.1-1%).
DirectionalAdverse Effects Interpretation
Amphetamines offer a comprehensive and aggressively efficient demolition of the human body, systematically dismantling everything from your brain's pleasure centers and cardiovascular stability to your teeth, skin, and sanity, all while convincing you it's a good idea.
Epidemiology/Prevalence
1In 2021, 16 million US adults reported lifetime amphetamine misuse.
Verified2Past-year amphetamine use disorder affected 1.3 million US people in 2021.
Verified3Among US high school seniors, 3.9% used amphetamines nonmedically in 2022.
Verified4Lifetime prevalence of amphetamine use in US college students is 11.5%.
Directional5In Australia, 7.2% of population aged 14+ used amphetamines lifetime in 2019.
Single source6US emergency department visits for amphetamines rose 103% from 2011-2019.
Verified72.7% of US 12th graders reported past-year Adderall misuse in 2022.
Verified8Global amphetamine-type stimulant seizures reached 200 tons in 2020.
Verified9In Europe, 1.3% of adults used amphetamines in past year (2022).
Directional10US prescription stimulant misuse among adults 18-25: 6.2% past year (2021).
Single source11Amphetamine use disorder prevalence in US military veterans: 5-10%.
Verified12Past-month nonmedical amphetamine use in US: 0.2% overall population (2021).
Verified13In Canada, 1.5% of students grade 7-12 used amphetamines nonmedically (2019).
Verified14Amphetamine overdose deaths in US: 3,452 in 2021.
Directional1575% of amphetamine users report polysubstance use.
Single source16In US, ADHD medication diversion rate: 16% of prescriptions.
Verified17Amphetamines in 25% of US ADHD treatment prescriptions.
Verified18Past-year misuse among US young adults 18-25: 10.1% (2021 NSDUH).
Verified19Amphetamine-related hospitalizations in US: 110,000 annually pre-COVID.
Directional20In New Zealand, 2.5% lifetime amphetamine use (2019).
Single source2150% of US college students obtain stimulants illicitly for studying.
Verified22Amphetamine use among US homeless: 15-20%.
Verified23Global ATS users: 36 million (2022 UNODC).
Verified24In Sweden, amphetamine most common illicit stimulant (1.2% past year).
Directional25US 8th graders nonmedical amphetamine use: 1.5% (2022).
Single source26Female amphetamine use rising faster than males in US (20% increase).
Verified27Amphetamine positive urine tests in workplace: 0.5% (2022).
Verified28Amphetamine cessation rates with behavioral therapy: 20-30% at 1 year.
VerifiedEpidemiology/Prevalence Interpretation
It's a grim irony that we've manufactured both a rampant stimulant crisis and the urgent need for stimulants to keep pace with it, with millions caught in the middle, self-medicating a burnout they can't outrun.
Legal/Regulation
1Amphetamine is Schedule II under US Controlled Substances Act.
Verified2Amphetamine possession illegal without prescription in most countries.
Verified3DEA production quotas for amphetamine: 25,000 kg in 2023.
Verified4Amphetamine trafficking penalties: up to 40 years US federal prison.
Directional5In UK, amphetamine is Class B drug; max 14 years possession.
Single source6Amphetamine precursors like phenylacetone regulated under UN conventions.
Verified7FDA requires REMS for amphetamine ADHD products due to abuse potential.
Verified8Amphetamine prescription limited to 30-day supply in some US states.
Verified9In Australia, amphetamine Schedule 8 (controlled drug).
Directional10Canada classifies amphetamine as Schedule I narcotic.
Single source11Amphetamine analoges like MDMA also scheduled internationally.
Verified12US state laws vary; some require database checks for amphetamine Rx.
Verified13Global amphetamine production estimated 500 tons illicit annually.
Verified14Amphetamine prescription fraud cases: 5,000 annually US.
Directional15EU Early Warning System monitors 50+ amphetamine NPS.
Single source16Amphetamine manufacturing labs seized: 1,200 in US 2022.
Verified17In Japan, amphetamine (shabu) is strictly prohibited; death penalty possible.
Verified18Prescription amphetamine sales US: $5 billion in 2022.
Verified19UN 1988 Convention schedules amphetamine precursors.
Directional20Amphetamine theft from pharmacies: 500 incidents/year US.
Single source21In Mexico, amphetamine production fuels 20% of cartel revenue.
Verified22US amphetamine import quotas tightly controlled by DEA.
Verified23Amphetamine analog scheduling under US Analog Act.
VerifiedLegal/Regulation Interpretation
Despite its legitimate medical use as a potent Schedule II prescription for ADHD, the global statistics paint amphetamine as a high-stakes molecule living a perilous double life, fueling a $5 billion pharmaceutical industry while simultaneously generating an estimated 500 tons of illicit production that bankrolls cartels, floods markets with dangerous analogs, and keeps law enforcement from Tokyo to Texas working overtime with severe penalties, strict quotas, and international conventions all struggling to contain its powerful and deeply abused potential.
Medical Uses
1Amphetamine is used to treat ADHD in children over 3 years old.
Verified2Adderall (mixed amphetamine salts) is approved for narcolepsy.
Verified3Dextroamphetamine (Dexedrine) treats ADHD at doses 5-40 mg/day.
Verified4Amphetamines improve attention and reduce hyperactivity in 70-80% of ADHD patients.
Directional5Lisdexamfetamine (Vyvanse) is a prodrug of dextroamphetamine for ADHD.
Single source6Amphetamine doses for obesity treatment were historically 5-30 mg/day.
Verified7Evekeo (amphetamine sulfate) approved for ADHD and exogenous obesity.
Verified8Amphetamines increase wakefulness in narcolepsy patients by 4-6 hours.
Verified9In treatment-resistant depression, amphetamines show 50% response rate adjunctively.
Directional10Amphetamine promotes weight loss of 0.5-1 kg/week in short-term obesity therapy.
Single source11Mydayis (extended-release amphetamines) for ADHD in ages 13+ up to 50 mg/day.
Verified12Amphetamines used off-label for treatment-emergent sexual dysfunction in SSRI users.
Verified13Amphetamine used in veterinary medicine for lethargy.
Verified14Amphetamines effective in 75% of narcolepsy cataplexy cases adjunctively.
Directional15Zenzedi (dextroamphetamine) for ADHD starting 2.5 mg.
Single source16ProCentra (liquid dextroamphetamine) for ADHD ages 6+.
Verified17Amphetamine reduces fatigue in multiple sclerosis patients (off-label).
Verified18In Parkinson's, amphetamines improve bradykinesia temporarily.
Verified19Historical use for asthma; bronchodilation via beta-2 agonism.
Directional20Amphetamine paste used in some dental applications historically.
Single source21Adzenys XR-ODT (amphetamine) for ADHD ages 6+.
VerifiedMedical Uses Interpretation
This whirlwind tour of amphetamine’s medical resume reveals a stimulant that, when properly prescribed, is a remarkably versatile Swiss Army knife for the nervous system—treating everything from attention deficits and sleep attacks to stubborn depression and even veterinary lethargy, all while sternly reminding us it’s a powerful tool, not a toy.
Pharmacology
1Amphetamine was first synthesized in 1887 by Romanian chemist Lazăr Edeleanu.
Verified2The chemical formula of amphetamine is C9H13N.
Verified3Amphetamine has a molecular weight of 135.21 g/mol.
Verified4Amphetamine is a chiral molecule with dextroamphetamine being the more potent enantiomer.
Directional5Amphetamine acts primarily by releasing monoamines like dopamine, norepinephrine, and serotonin.
Single source6Oral bioavailability of amphetamine is approximately 70-90%.
Verified7Half-life of amphetamine in adults is 9-11 hours.
Verified8Amphetamine increases synaptic dopamine by inhibiting reuptake and promoting release.
Verified9Peak plasma concentration of amphetamine occurs 3 hours after oral dose.
Directional10Amphetamine pKa is 9.9, making it a weak base.
Single source11Dextroamphetamine has 3-5 times the potency of levoamphetamine on CNS.
Verified12Amphetamine is metabolized primarily by CYP2D6 in the liver.
Verified13Volume of distribution for amphetamine is 3-4 L/kg.
Verified14Amphetamine crosses the blood-brain barrier rapidly due to lipophilicity.
Directional15Therapeutic plasma levels of amphetamine range 20-50 ng/mL.
Single source16Amphetamine sulfate is the most common pharmaceutical form.
Verified17LogP (octanol-water partition coefficient) of amphetamine is 1.76.
Verified18Amphetamine melting point is 102-104°C.
Verified19Amphetamine is excreted 30-40% unchanged in urine.
Directional20Urinary pH affects amphetamine excretion; acidic urine increases elimination.
Single source21Amphetamine was used in WWII by militaries for alertness.
Verified22Amphetamine elevates extracellular dopamine by 1000% at high doses.
Verified23Norepinephrine release by amphetamine is 10-fold baseline.
Verified24Amphetamine VMAT2 inhibition leads to cytoplasmic monoamine accumulation.
Directional25Levoamphetamine contributes more to peripheral effects.
Single source26Protein binding of amphetamine is <20%.
VerifiedPharmacology Interpretation
Born in 1887 as a humble weak base with a pKa of 9.9, amphetamine has since perfected the art of overachievement, hijacking our monoamine systems to flood synapses with a tenfold surge of norepinephrine and, at its most ambitious, a thousand percent dopamine deluge, all while expertly navigating the body's pH to prolong its own dramatic performance.
Sources & References
- Reference 1ENen.wikipedia.orgVisit source
- Reference 2PUBCHEMpubchem.ncbi.nlm.nih.govVisit source
- Reference 3NCBIncbi.nlm.nih.govVisit source
- Reference 4NATUREnature.comVisit source
- Reference 5PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 6DRUGSdrugs.comVisit source
- Reference 7FDAfda.govVisit source
- Reference 8ACCESSDATAaccessdata.fda.govVisit source
- Reference 9NIDAnida.nih.govVisit source
- Reference 10SAMHSAsamhsa.govVisit source
- Reference 11MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 12AIHWaihw.gov.auVisit source
- Reference 13CDCcdc.govVisit source
- Reference 14UNODCunodc.orgVisit source
- Reference 15EMCDDAemcdda.europa.euVisit source
- Reference 16CCSAccsa.caVisit source
- Reference 17DEAdea.govVisit source
- Reference 18FEDERALREGISTERfederalregister.govVisit source
- Reference 19GOVgov.ukVisit source
- Reference 20TGAtga.gov.auVisit source
- Reference 21CANADAcanada.caVisit source
- Reference 22DEADIVERSIONdeadiversion.usdoj.govVisit source
- Reference 23HPAhpa.org.nzVisit source
- Reference 24QUESTDIAGNOSTICSquestdiagnostics.comVisit source
- Reference 25IQVIAiqvia.comVisit source